Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Inhaltsangabe
I. Atherosclerosis And Cardiovascular Disease.- 1. PPAR-Alpha in Lipid and Lipoprotein Metabolism, Vascular Inflammation and Atherosclerosis.- 2. The Choice of an Appropriate Animal Species in the Study of Chlamydia pneumoniae as an Atherogenic Agent.- 3. Endothelial Cell Dysfunction-A Key Factor in Atherogenesis and its Reversal (Laboratory and Clinical Study).- 4. Biochemical Mechanisms of Hyperhomocysteinemia in Atherosclerosis: Role of Chemokine Expression.- 5. Oxyradicals and Hypercholesterolemic Atherosclerosis.- 6. Identification, Regulation and Function of LOX-1, A Novel Receptor for Ox-LDL.- 7. Atherosclerosis and Angiotensin II in Hypercholesterolemia and Diabetes. A Role for ATt Receptors Beyond Hypertension.- 8. Basic and Clinical Results of New Statin: Pitavastatin.- 9. Reducing Cardiovascular Risk With HMG CoA Reductase Inhibitors, Potential Contribution From Platelets.- 10. Rapamycin-Sensitive Signal Transduction Pathways and the Control of Adipogenesis.- II. Hypertension.- 11. Genetic Predisposition to Hypertension and Cardiovascular Disease.- 12. Role of Sympathetic Nervous System in Hypertension.- 13. Role of Hypothalamic Peptides in the Development of Hypertension.- 14. Myosin Light Chain Kinase in Endothelial Cell Calcium Signaling and Endothelial Functions.- 15. Sarpogrelate Inhibits Genes Involved in Vascular Neointimal Hyperplasia and Remodeling.- 16. A Nutritional Approach to Prevent High Blood Pressure.- 17. Cardiovascular and Renal Actions of Leptin.- 18. Brain Na, K-ATPase Enzymatic Activity and Cardiovascular Regulation.- 19. Development of Transdermal and Transbuccal Drug Delivery Systems for Cardioactive Drugs with Special Reference to Anti-Hypertensive Agents.- 20. Insulin Resistance and Experimental Hypertension.- III. DiabetesMellitus.- 21. New Paradigm for Insulin Resistance: The HISS Story.- 22. Vanadium Effects in Diabetes.- 23. Dyslipoproteinemia and Fibrinolysis.- 24. Endothelins and Cardiovascular Disease in Diabetes.- 25. Usefulness of 5-HT2A Receptor Antagonists for the Treatment of Cardiovascular Complications in Diabetes.- 26. Selective Attenuation of Enhanced Angiotensin II Mediated Responses in the Streptozotocin Diabetic Rat Thoracic Aorta by Tempol.- 27. Role of Renin-Angiotensin System in Diabetic Heart Dysfunction and Changes in Phospholipase C Activity.- 28. Regulation of Cardiac Function in Diabetes.- 29. Diabetes and Cardiac Dysfunction.- 30. Mechanisms Underlying Contractile Dysfunction in Streptozotocin-Induced Type 1 and Type 2 Diabetic Cardiomyopathy.- 31. Protein Kinase C Signaling and Expression of the Diabetic Cardiac Phenotype.- 32. Oxidative Stress in Cardiovascular Complications of Diabetes.- 33. Augmented Energy Transfer in Rat Heart Mitochondria: Compensatory Response to Abnormal Household of Energy in Acute Diabetes.- 34. Ketosis, Tumor Necrosis Factor-a and Cardiovascular Disease in Type-1 Diabetic Patients.- 35. Epigenetic Alterations in Diabetic Cardiomyopathy.
I. Atherosclerosis And Cardiovascular Disease.- 1. PPAR-Alpha in Lipid and Lipoprotein Metabolism, Vascular Inflammation and Atherosclerosis.- 2. The Choice of an Appropriate Animal Species in the Study of Chlamydia pneumoniae as an Atherogenic Agent.- 3. Endothelial Cell Dysfunction-A Key Factor in Atherogenesis and its Reversal (Laboratory and Clinical Study).- 4. Biochemical Mechanisms of Hyperhomocysteinemia in Atherosclerosis: Role of Chemokine Expression.- 5. Oxyradicals and Hypercholesterolemic Atherosclerosis.- 6. Identification, Regulation and Function of LOX-1, A Novel Receptor for Ox-LDL.- 7. Atherosclerosis and Angiotensin II in Hypercholesterolemia and Diabetes. A Role for ATt Receptors Beyond Hypertension.- 8. Basic and Clinical Results of New Statin: Pitavastatin.- 9. Reducing Cardiovascular Risk With HMG CoA Reductase Inhibitors, Potential Contribution From Platelets.- 10. Rapamycin-Sensitive Signal Transduction Pathways and the Control of Adipogenesis.- II. Hypertension.- 11. Genetic Predisposition to Hypertension and Cardiovascular Disease.- 12. Role of Sympathetic Nervous System in Hypertension.- 13. Role of Hypothalamic Peptides in the Development of Hypertension.- 14. Myosin Light Chain Kinase in Endothelial Cell Calcium Signaling and Endothelial Functions.- 15. Sarpogrelate Inhibits Genes Involved in Vascular Neointimal Hyperplasia and Remodeling.- 16. A Nutritional Approach to Prevent High Blood Pressure.- 17. Cardiovascular and Renal Actions of Leptin.- 18. Brain Na, K-ATPase Enzymatic Activity and Cardiovascular Regulation.- 19. Development of Transdermal and Transbuccal Drug Delivery Systems for Cardioactive Drugs with Special Reference to Anti-Hypertensive Agents.- 20. Insulin Resistance and Experimental Hypertension.- III. DiabetesMellitus.- 21. New Paradigm for Insulin Resistance: The HISS Story.- 22. Vanadium Effects in Diabetes.- 23. Dyslipoproteinemia and Fibrinolysis.- 24. Endothelins and Cardiovascular Disease in Diabetes.- 25. Usefulness of 5-HT2A Receptor Antagonists for the Treatment of Cardiovascular Complications in Diabetes.- 26. Selective Attenuation of Enhanced Angiotensin II Mediated Responses in the Streptozotocin Diabetic Rat Thoracic Aorta by Tempol.- 27. Role of Renin-Angiotensin System in Diabetic Heart Dysfunction and Changes in Phospholipase C Activity.- 28. Regulation of Cardiac Function in Diabetes.- 29. Diabetes and Cardiac Dysfunction.- 30. Mechanisms Underlying Contractile Dysfunction in Streptozotocin-Induced Type 1 and Type 2 Diabetic Cardiomyopathy.- 31. Protein Kinase C Signaling and Expression of the Diabetic Cardiac Phenotype.- 32. Oxidative Stress in Cardiovascular Complications of Diabetes.- 33. Augmented Energy Transfer in Rat Heart Mitochondria: Compensatory Response to Abnormal Household of Energy in Acute Diabetes.- 34. Ketosis, Tumor Necrosis Factor-a and Cardiovascular Disease in Type-1 Diabetic Patients.- 35. Epigenetic Alterations in Diabetic Cardiomyopathy.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
